[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:burkitt-lymphoma:hiv-infection":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Burkitt Lymphoma","HIV Infection",5,[8,16,23,30,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05389423","Pomalidomide and Dose-Adjusted EPOCH +\u002F- Rituximab for HIV-Associated Lymphomas",[12],"Phase 1","RECRUITING","2026-08-26T02:19:23.493898Z","2026-05-05T02:35:31.746900Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[20],"Phase 1\u002FPhase 2","2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[27],"Phase 2","2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.206546Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[27],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.261789Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients",[27],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:26.753431Z"]